Company news
IN8bio, Inc. news in 2021
IN8bio, Inc.'s news releases, calls and decks from 2021, newest first.
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
December 15, 2021
IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer
December 8, 2021
IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
November 15, 2021
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 9, 2021
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
November 3, 2021
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
October 26, 2021
IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 9, 2021
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
August 10, 2021
IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
August 3, 2021
IN8bio Announces Pricing of Initial Public Offering
July 29, 2021